Imatinib strongly suppresses Warburg effect through the down-regulation of PTBP1.
Fatty-acid oxidation (FAO) supports glucose-independent survival in imatinib-treated cells.
Inactivation of BCR-ABL activates compensatory FAO.
AIC-47 perturbs both glycolysis and FAO.
The inhibition of glycolysis and FAO can be effective for the CD34+ fraction.